Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
// Azharuddin Sajid Syed Khaja 1, 2, * , Salman M. Toor 1, 2, * , Haytham El Salhat 3, 4 , Issam Faour 4 , Navid Ul Haq 5 , Bassam R. Ali 6 , Eyad Elkord 1, 2, 7 1 Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar 2 Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates 3 Oncology Department, Al Noor Hospital, Abu Dhabi, United Arab Emirates 4 Surgery Department, Tawam Hospital, Al Ain, United Arab Emirates 5 Pathology Department, Tawam Hospital, Al Ain, United Arab Emirates 6 Department of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates 7 Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom * These authors contributed equally to this work Correspondence to: Eyad Elkord, email: eelkord@hbku.edu.qa , eyad.elkord@manchester.ac.uk Keywords: regulatory T cells, FoxP3, helios, immune checkpoint receptors, primary breast cancer Received: February 21, 2017 Accepted: March 16, 2017 Published: March 25, 2017 ABSTRACT Immunosuppressive cells such as regulatory T cells (Tregs) have an ambiguous role in breast cancer prognosis, with studies reporting both positive and negative correlations between Treg infiltration and prognosis. This discrepancy could be due to the different immunosuppressive molecules present in these cells. In the present study, we phenotypically characterize different Treg subsets infiltrating the tumor microenvironment (TME), compared to adjacent normal tissue and peripheral blood of primary breast cancer (PBC) patients. We report that the majority of tumor-infiltrating CD4 + and CD8 + T cells have terminally exhaustive phenotype as assessed by CD39 and PD-1 expressions. We also show that Tregs are accumulated in breast TME compared to normal tissue. Further characterization of Tregs showed that these are mainly FoxP3 + Helios + and express high levels of CTLA-4 and PD-1. This preferential accumulation of FoxP3 + Helios + Treg subset with co-expression of different immune inhibitory molecules might have a negative effect on breast cancer prognosis. Taken together, our results suggest that breast tumor cells might utilize Tregs, and different suppressive pathways involving CD39, PD-1 and CTLA-4 molecules in creating an immune-subversive environment for them to survive, and a dual blockade of these immunosuppressive molecules might be considered as an effective method in breast cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“For example, a study found that CCR4+ Tregs migrate to the tumor tissue through CCL22 secreted by ovarian cancer cells [47].”
BackgroundNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“Accumulation of CD8+ T cells in TT would have indicated a tumor-specific immune response as a protective function against cancer, but a high PD-1 expression in these cells, compared with NT, suggested a “T-cell anergy” state and their unresponsiveness against cancer cells [43].”
BackgroundCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · cited 2×
“The TME is usually enriched with infiltrating immune cells, which accumulate as a result of a possible host immune response against cancer [29].”
BackgroundCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · cited 1×
“Elevated levels of CD4+ T cells co-expressing CTLA-4 and PD-1 also support the dual blockade of these immunosuppressive pathways, which could be a more effective method for treating different cancers including breast [38, 39].”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“Furthermore, these pro-inflammatory FoxP3lo nonTregs have lower expression of CTLA-4 and TIGIT [53], indicating that immunosuppressive molecules on T cells and Tregs affect the outcome of the disease.”
BackgroundRegulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695 · cited 4×
“Recently, a critical role of CCL1/ CCR8 axis in the accumulation of FoxP3+ Tregs in breast the TME has also been reported [15].”
BackgroundResultInfluentialKim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Cited by
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Self-citationImmune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
Self-citationT cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, D., Xu, L., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0629-x · Cited by 272
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 237
The microbiome and the hallmarks of cancer
Fulbright, L. E., Ellermann, M., & Arthur, J. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006480 · Cited by 164
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1471137 · Cited by 159
Self-citationKumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
The Multifaceted Role of Regulatory T Cells in Breast Cancer
Kos, K., & de Visser, K. E. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042920-104912 · Cited by 58
Metadata
- Authors
- Khaja, A. S. S., Toor, S. M., El Salhat, H., Faour, I., Ul Haq, N., Ali, B. R., & Elkord, E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-03-25
- Volume
- 8
- Issue
- 20
- Pages
- 33159-33171
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2599346721
- Cited by
- 121
- References
- 15
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.